The association between glycogen synthase kinase 3 beta polymorphisms and Parkinson's disease susceptibility: A meta-analysis

• The meta-analysis of GSK3-β polymorphisms and PD risk was done for the first time.
• GSK3-β polymorphisms didn’t affect PD risk in the overall and Caucasian population.
• GSK3-β polymorphisms may reduce PD risk in the Eastern Asian population.

Previous studies on the association between glycogen synthase kinase 3 beta (GSK3-β) polymorphisms (rs334558 and rs6438552) and Parkinson's disease (PD) susceptibility remained inconsistent. Thus, the goal of this study was to re-examine their exact association by a meta-analysis. All eligible studies were identified by a systematic literature search of multiple databases. Six studies (3105 cases and 4387 controls) on rs334558 and six studies (2579 cases and 4091 controls) on rs6438552 were included. The quality of these studies was generally good according to the Newcastle–Ottawa Scale (NOS). The meta-analysis showed null association between the two variants and PD susceptibility in all genetic models from the overall or Caucasian population. However, the analysis of rs334558 revealed that the risk of PD decreased in heterozygote, dominant or additive models (OR = 0.60, 95% CI: 0.48, 0.74; OR = 0.63, 95% CI: 0.51, 0.78; OR = 0.82, 95% CI: 0.71, 0.94, respectively) from the Eastern Asian population. Moreover, the analysis on the homozygote, heterozygote, dominant or additive models suggested that rs6438552 also reduced the PD risk (OR = 0.45, 95% CI: 0.24, 0.84; OR = 0.62, 95% CI: 0.39, 0.97; OR = 0.57, 95% CI: 0.37, 0.87; OR = 0.66, 95% CI: 0.49, 0.88, respectively) in the Eastern Asian population. Together, the findings suggest that the two variants both reduced the risk of PD in the Eastern Asian subgroup but not in the overall and Caucasian populations, which should be cautiously interpreted because of limited number of included studies.